Skip to content
Biodatica
Start free

Lumicell, Inc.

Boston, Massachusetts

OncologymicrobiomePhase II
Compare Sign in to watch

What changed

Phase I trial registered: ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

4w agoTrial registeredJun 22, 2026Source filing (opens the source filing in a new tab)

Momentum

82no change

Momentum 82 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,850 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Feb 24, 2026

    Colorectal Cancer Prevention, Colorectal Adenoma · RECRUITING · sponsor: Massachusetts General Hospital · Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

    ClinicalTrials.gov · NCT07095517 (opens the source filing in a new tab)

  2. Trial

    EARLY_PHASE1 registered

    Jun 3, 2022

    Colorectal Cancer · ACTIVE_NOT_RECRUITING · sponsor: Massachusetts General Hospital · ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension

    ClinicalTrials.gov · NCT05056896 (opens the source filing in a new tab)

  3. Trial

    PHASE1/PHASE2 registered

    Aug 4, 2016

    Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer · RECRUITING · sponsor: Lumicell, Inc. · Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

    ClinicalTrials.gov · NCT02584244 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources